None

Mavacamten (mavacamten) is a cardiac myosin inhibitor. Its pharmacological mechanism determines that it can not only improve left ventricular outflow tract obstruction, but also have a certain impact on myocardial contractility. Overseas literature generally divides adverse reactions into functional changes, digestive system symptoms, cardiac monitoring abnormalities, etc. Most of them are controllable and reversible mild to moderate reactions. For patients with hypertrophic cardiomyopathy (HCM), understanding possible adverse reactions in advance and mastering coping strategies can help improve treatment safety and compliance.

Fatigue, dizziness, and mild weakness are common experiences during medication, and are usually related to decreased myocardial contractility. In this case, patients are advised to avoid sudden increases in exercise and to maintain regular monitoring of cardiac ultrasound so that dosage can be adjusted earlier if abnormalities appear. Some patients may experience stomach discomfort, loss of appetite, and mild nausea. This type of situation is common in people who are sensitive to drugs. They can choose an appropriate eating time or perform simple symptomatic treatment under the guidance of a doctor. In addition, some overseas reports mention the risk of heart rate changes or bradycardia. Therefore, baseline cardiac function values u200bu200bare required to be established before treatment is officially started, and then reviewed regularly every few weeks to ensure that systolic function is maintained within a safe range.

If the patient experiences obvious chest tightness, a sharp decrease in activity tolerance, or palpitations, he should seek medical attention immediately to rule out a decrease in cardiac function. Overseas experience points out that reducing the dose or temporarily discontinuing the drug can usually restore normal cardiac function, so the adverse reactions of this type of drug are well reversible. For patients undergoing long-term treatment, maintaining a stable daily routine, avoiding excessive stress, and maintaining a reasonable salt intake are also important parts of auxiliary management.

Overall, most of the adverse reactions of Mavaceta can be effectively controlled through standardized monitoring and early intervention, and patients can maintain a high level of medication safety under the management of a professional team.

Reference materials:https://bnf.nice.org.uk/drugs/mavacamten/